Table 1.
Participant demographics at baseline for participants who met the primary endpoint at Week 24
| Characteristics | ENG study (n = 75) | LNG study (n = 78) | ||||
|---|---|---|---|---|---|---|
| RPV (n = 28) | DRV/r (n = 29) | Control (n = 18) | RPV (n = 30) | DRV/r (n = 28) | Control (n = 19) | |
| Age (years) | 36a (30–39) | 37b (32–41) | 32 (26–35) | 34 (29–37) | 38c (35–42) | 33 (31–36) |
| Weight (kg) | 60 (54–72) | 59 (47–65) | 60 (50–69) | 56d (51–64) | 58e (50–68) | 65 (59–74) |
| BMI (kg/m2) | 24.1 (21.3–29.5) | 23.2 (20.9–25.3) | 23.7 (20.5–28.3) | 21.9f (19.6–24.4) | 24.0 (21.2–28.4) | 26.6 (23.2–28.7) |
| Marital status, n (%) | ||||||
| Single | 18 (64.3) | 18 (62.1) | 11 (61.1) | 12 (40.0) | 10 (35.7) | 8 (40.0) |
| Married | 10 (35.7) | 11 (37.9) | 7 (38.9) | 18 (60.0) | 18 (64.3) | 12 (60.0) |
| Parity | 3 (2–5) | 3 (3–4) | 3 (3–5) | 3 (2–4) | 4 (3–5) | 3 (2–4) |
| Highest educational level, n (%) | ||||||
| None | 2 (7.1) | 4 (13.8) | 1 (5.6) | 3 (10.0) | 1 (3.6) | 0 |
| Primary | 15 (53.6) | 16 (55.2) | 10 (55.6) | 8 (26.7) | 14 (50.0) | 10 (50.0) |
| Secondary+ | 11 (39.3) | 9 (31.0) | 7 (38.8) | 19 (63.3) | 13 (46.4) | 10 (50.0) |
| CD4 count (cells/mL) | 738 (609–1019) | 730 (480–801) | N/A | 762 (564–1045) | 719 (407–917) | N/A |
Unless indicated, results are presented as median (IQR) and not statistically different between groups. Control, women without HIV; DRV/r, darunavir/ritonavir-based ART group; ENG, etonogestrel; LNG, levonorgestrel; N/A, not applicable; RPV, rilpivirine-based ART group.
a
RPV versus control; P = 0.048; Wilcoxon rank-sum.
b
DRV versus control; P = 0.003; Wilcoxon rank-sum.
c
DRV versus control; P = 0.002; Wilcoxon rank-sum.
d
RPV versus control; P = 0.008; Wilcoxon rank-sum.
e
DRV versus control; P = 0.034; Wilcoxon rank-sum.
f
RPV versus control; P = 0.007; Wilcoxon rank-sum.